[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370534-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370534-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","non-steroidal-anti-inflammatory-medication-use-and-endometrial-cancer-survival-a-population-based-norwegian-cohort-study","Non-steroidal anti-inflammatory medication use and endometrial cancer survival - A population-based Norwegian cohort study","","Nonsteroidal anti-inflammatory drugs (NSAIDs) have shown survival benefits in some cancers, yet evidence in endometrial cancer remains inconsistent. This nationwide Norwegian cohort study assessed aspirin and nonaspirin NSAID use in relation to endometrial cancer-specific and all-cause death. Data were linked from the Cancer Registry of Norway and the Norwegian Prescription database for patients diagnosed in 2004–2018. Post-diagnosis exposure required at least three consecutive prescriptions, and Cox regression estimated hazard ratios while adjusting for relevant factors. Results showed aspirin use associated with higher all-cause mortality and increased cancer-specific risk with NA-NSAIDs, including dose-response findings for cancer-specific death.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/non-steroidal-anti-inflammatory-medication-use-and-endometrial-cancer-survival-a-population-based-norwegian-cohort-study/370534/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/non-steroidal-anti-inflammatory-medication-use-and-endometrial-cancer-survival-a-population-based-norwegian-cohort-study/370534.png","ImageObject",300,407,{"name":42,"@type":43},"Sophia Brooks","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How did the study define aspirin and nonaspirin NSAID exposure after endometrial cancer diagnosis?","Question",{"text":63,"@type":64},"Post-diagnosis exposure required at least three consecutive prescriptions with at least 30 days after the endometrial cancer diagnosis. Pre-diagnosis use required at least two filled prescriptions within the six months before diagnosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What data sources were used in this nationwide cohort study?",{"text":68,"@type":64},"The study linked information from the Cancer Registry of Norway with The Norwegian Prescription database.",{"name":70,"@type":61,"acceptedAnswer":71},"What association did aspirin and nonaspirin NSAID use show with mortality?",{"text":72,"@type":64},"Aspirin use was associated with a higher risk of all-cause death versus nonusers. Nonaspirin NSAIDs increased cancer-related death risk, and higher cumulative doses were linked to significantly higher cancer-specific death risk.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370534,1790386518,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","DOI: 10.1002/ijc.35363  \nRES EARCH A RTICLE  \nCa ncer Epidemiology  \nNon-steroidal anti-inflammatory medication use and endometrial cancer survival: A population-based Norwegian cohort study  \nAla Jabri Haug 1,2  | Nathalie Støer 3 | Hilde Langseth 3,4 | Franziska Siafarikas 1,2 | Edoardo Botteri 3,5 | Renée Turzanski Fortner 3,6 | Kristina Lindemann 2,7  \n1Akershus University Hospital, Lørenskog, Norway  \n2Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway 3Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway  \n4Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK  \n5Section for Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway 6Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany 7Department of Surgical Oncology, Section for Gynecological Oncology, Oslo University Hospital, Oslo, Norway  \nCorrespondence  \nKristina Lindemann, Department of Surgical Oncology, Section for Gynaecological Oncology, The Norwegian Radium Hospital, Oslo University Hospital, PB 4953 Nydalen, 0424 Oslo, Norway.  \nEmail: [klinde@ous-hf.no](klinde@ous-hf.no)  \n[Correction added on 28 April 2025, after first online publication: The copyright line was changed.]  \nAbstract  \nWhile nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to improve survival in certain cancers, data in patients with endometrial cancer (EC) is conflicting. This study investigated use of aspirin and nonaspirin NSAIDs (NA-NSAIDs) and EC-specific—and allcause death. This nationwide cohort study linked data from the Cancer Registry of Norway with The Norwegian Prescription database. Patients diagnosed with EC from 2004 to 2018 were included. Post-diagnosis exposure to aspirin and NA-NSAIDs was defined as ≥3 consecutive prescriptions ≥30 days after EC diagnosis, with pre-diagnosis use as ≥2 filled prescriptions \u003C6 months prior to diagnosis. Follow-up started 10 months after diagnosis. Hazard ratios for the risk of death were calculated with multivariable Cox-regression models. Our study population included 7751 individuals with EC, 685 (9%) were aspirin users and 620 (8%) were NA-NSAIDs users. The median follow-up time was 5.0 years, with 1518 (20%) deaths observed (n = 728 (9%) EC-specific). In multivariable analysis, aspirin use was significantly associated with a 19% higher risk of all-cause death compared to nonusers (HR = 1. 19, 95% CI [1.01–1.41]). The association was stronger among combined preand postdiagnosis use (HR = 1.35 [1.12–1.64]). NA-NSAIDs use increased risk of cancerrelated death (HR = 1.25 [0.99–1.58]) and there was a dose–response association with significantly higher risk of cancer-specific death with higher cumulative doses (HR = 1.33 [1.02–1.75]). We found a higher risk of cancer-specific—and all-cause death among patients that used aspirin and NA-NSAIDs after a diagnosis of EC. Further studies on the biological mechanisms underlying these associations are needed.  \nKEYWOR DS  \naspirin, endometrial cancer, NSAIDS, survival, tertiary prevention  \nWhat's New?  \nAspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) may improve survival in certain types of cancer, but evidence has been inconclusive so far regarding their effect on endometrial  \nRenée Turzanski Fortner and Kristina Lindemann have contributed equally to this study.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2025 The Author(s) . International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.  \ncancer survival. Here, the authors present data from a large population-based cohort study in Norway, inclu","cbCaidw98ZTc2Nso","https://ap.wps.com/l/cbCaidw98ZTc2Nso","pdf",774212,11,"English","# Abstract\n# Introduction\n## Background and epidemiology of endometrial cancer\n## Rationale for NSAIDs and aspirin\n## Evidence gap and study purpose","[{\"question\":\"How did the study define aspirin and nonaspirin NSAID exposure after endometrial cancer diagnosis?\",\"answer\":\"Post-diagnosis exposure required at least three consecutive prescriptions with at least 30 days after the endometrial cancer diagnosis. Pre-diagnosis use required at least two filled prescriptions within the six months before diagnosis.\"},{\"question\":\"What data sources were used in this nationwide cohort study?\",\"answer\":\"The study linked information from the Cancer Registry of Norway with The Norwegian Prescription database.\"},{\"question\":\"What association did aspirin and nonaspirin NSAID use show with mortality?\",\"answer\":\"Aspirin use was associated with a higher risk of all-cause death versus nonusers. Nonaspirin NSAIDs increased cancer-related death risk, and higher cumulative doses were linked to significantly higher cancer-specific death risk.\"}]","Non-steroidal anti-inflammatory medication use and endometrial cancer survival - A population-based Norwegian cohort study | PDF",1790189023,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c601baaa3d0413c8dba7401d18f0723d.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a798936f8cc60dddc6b3f3ac816d0cf2.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f17216e94a603821a9e841edf1526c72.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33e334faa7b79682e430eaeb957f4414.webp",980,1287]